Home › Funds › NORRIS PERNE & FRENCH LLP/MI › ABT

NORRIS PERNE & FRENCH LLP/MI position in ABT

ABBOTT LABORATORIES · Health Care

NORRIS PERNE & FRENCH LLP/MI reported holding 334,455 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$33.1M, representing 1.44% of its reported portfolio and ranking #20 among its reported holdings. NORRIS PERNE & FRENCH LLP/MI has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)334.45K sh
Reported value held$33.05M
Portfolio Weight1.44%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How NORRIS PERNE & FRENCH LLP/MI's ABT position evolved

NORRIS PERNE & FRENCH LLP/MI first disclosed a stake in ABT in Q3 2023 at 140,224 shares (US$13.6M). The position peaked in Q3 2026 at 334,455 shares, worth US$33.1M. Across 13 filings, NORRIS PERNE & FRENCH LLP/MI increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 334,455 shares valued at US$33.1M — an increase of 176,750 shares quarter over quarter.. Notable position changes include a 67% trim in Q1 2026 (shares fell 11% over the following quarter), a 129% increase in Q2 2026 (shares rose 10% over the following quarter), a 112% increase in Q3 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 140.22K $13.58M New
Q4 2023 142.58K $15.69M Add
Q1 2024 144.34K $16.41M Add
Q2 2024 228.76K $23.77M Add
Q3 2024 226.22K $25.79M Reduce
Q4 2024 226.31K $25.60M Hold
Q1 2025 223.23K $29.61M Reduce
Q2 2025 220.46K $29.98M Reduce
Q3 2025 215.14K $28.82M Reduce
Q4 2025 209.49K $26.25M Reduce
Q1 2026 68.83K $7.07M Reduce
Q2 2026 157.71K $14.31M Add
Q3 2026 334.45K $33.05M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has NORRIS PERNE & FRENCH LLP/MI held ABT?

NORRIS PERNE & FRENCH LLP/MI has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is NORRIS PERNE & FRENCH LLP/MI's current position in ABT?

As of Q3 2026, NORRIS PERNE & FRENCH LLP/MI holds 334.45K shares of ABT (ABBOTT LABORATORIES), valued at $33.05M, representing 1.44% of its reported portfolio and ranking #20.

Has NORRIS PERNE & FRENCH LLP/MI been buying or selling ABT?

In the latest 13F filing (Q3 2026), NORRIS PERNE & FRENCH LLP/MI increased its position in ABT. The position peaked in Q3 2026 at 334.45K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.